MacroGenics Inc to Review Flotetuzumab Data Presented at the ASH Annual Meeting - Call Transcript
Good evening. We will begin the MacroGenics 2019 AHS (sic) [ASH] conference call in just a moment. (Operator Instructions) At this point, I will turn the call over to Anna Krassowska, Vice President, Investor Relations and Corporate Communications of MacroGenics.
Thank you. Good evening, and welcome to the MacroGenics conference call to review the flotetuzumab data presented at the American Society of Hematology Annual Meeting here in Orlando, and to discuss clinical development plans for the program. The presentation that accompanies this conference call is available under the Investors tab on our website at macrogenics.com. You can also listen to this conference call via webcast on our website, where it will be archived for 30 days beginning approximately 2 hours after the call is completed.
Before we begin, I would like to alert listeners that today's discussion will include statements about the company's future expectations, plans and prospects that constitute forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |